Where We Show Up

Conferences, company updates and press releases

Events & Updates

Where to find and read about us

Data on Anti-4CB1 Published in Molecular Cancer Therapeutics Journal (AACR)

August 20, 2026 Preclinical data for lead asset Anti-4CB1, a first-in-class HVEM-blocking antibody

AstraZeneca oncology veteran Alan Barge named CEO of 4C Biomed

August 18, 2026 Dr. Barge brings over 25 years in oncology drug development and joins as 4C Biomed prepares to enter the clinic

U.S. Patent Granted for Anti-HVEM Antibody Program

July 21, 2026 U.S. Patent No. 12,686,722, "Anti-HVEM Antibodies and Use Thereof" extending protection for the lead program in the USA

Chinese Patent Granted for Anti-HVEM Antibody Program

January 10, 2025 Chinese Patent No. CN 114026124 B, "Anti-HVEM Antibodies and Use Thereof" extending protection for the lead program in China

This website uses cookies and similar technologies such as web beacons and pixels (collectively: “cookies”). These cookies are required in order to load our website or to enable you to use certain services that our website offers. We cannot provide you with access to the website or services without these cookies, and therefore these cookies cannot be disabled. For more details, you can read our privacy policy here.